Considerations when selecting an antidepressant: a narrative review for primary care providers treating adults with depression

References

• Villarroel MA, Terlizzi EP. Symptoms of depression among adults: united States. NCHS Data Brief. 2019;2020(379):1–8.
   Google Scholar
• Delphin-Rittmon ME. In: SAMHSA: key substance use and mental health indicators in the United States: results from the 2020 national survey on drug use and health [Internet]. Jul 2020. Rockville (MD): Substance Abuse and Mental Health Services Administration. Available fromhttps://www.samhsa.gov/data/sites/default/files/reports/slides-2020-nsduh/2020NSDUHNationalSlides072522.pdf
   Google Scholar
• Malhi GS, Bell E, Singh AB, et al. The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: major depression summary. Bipolar Disord. 2020;22(8):788–804.
   PubMed Web of Science ®Google Scholar
• Sakai C, Tsuji T, Nakai T, et al. Change in antidepressant use after initiation of ADHD medication in Japanese adults with comorbid depression: a real-world database analysis. Neuropsychiatr Dis Treat. 2021;17:3097–3108.
   PubMedGoogle Scholar
• Park LT, Zarate CA Jr. Depression in the primary care setting. N Engl J Med. 2019;380(6):559–568.
   PubMed Web of Science ®Google Scholar
• Ferenchick EK, Ramanuj P, Pincus HA. Depression in primary care: part 1—screening and diagnosis. BMJ. 2019;365:l794.
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5. 5th. Washington (DC): American Psychiatric Publishing; 2013.
   Google Scholar
• Gelenberg AJ, Freeman MP, Markowitz JC, et al. In: Practice guideline for the treatment of patients with major depressive disorder[Internet] 3rd. Washington (DC): American Psychiatric Association; 2010. Available fromhttp://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx
   Google Scholar
• Ban TA. The role of serendipity in drug discovery. Dialogues Clin Neurosci. 2006;8(3):335–344.
   PubMedGoogle Scholar
• Gartlehner G, Gaynes BN, Amick HR, et al. Comparative benefits and harms of antidepressant, psychological, complementary, and exercise treatments for major depression: an evidence report for a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2016;164(5):331–341.
   Google Scholar
• Ljungberg T, Bondza E, Lethin C. Evidence of the importance of dietary habits regarding depressive symptoms and depression. Int J Environ Res Public Health. 2020;17(5):1616.
   PubMed Web of Science ®Google Scholar
• Santarsieri D, Schwartz TL. Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs Context. 2015;4:212290.
   PubMedGoogle Scholar
• Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives. Lancet. 2012;379(9820):1045–1055.
   PubMed Web of Science ®Google Scholar
• aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ. 2009;180(3):305–313.
   PubMed Web of Science ®Google Scholar
• Yamada Y, Yoshikawa T, Naganuma F, et al. Chronic brain histamine depletion in adult mice induced depression-like behaviours and impaired sleep-wake cycle. Neuropharmacology. 2020;175:108179.
   PubMed Web of Science ®Google Scholar
• Katzman MA, Bilkey TS, Chokka PR, et al. Adult ADHD and comorbid disorders: clinical implications of a dimensional approach. BMC Psychiatry. 2017;17(1):302.
   PubMed Web of Science ®Google Scholar
• FDA. In: Depression medicines [Internet]. September 2019. Silver Spring (MD): Food and Drug Administration. Available fromhttps://www.fda.gov/media/132665/download
   Google Scholar
• Papakostas GI, Jackson WC, Rafeyan R, et al. Overcoming challenges to treat inadequate response in major depressive disorder. J Clin Psychiatry. 2020;81:3.
   Web of Science ®Google Scholar
• Luo Y, Kataoka Y, Ostinelli EG, et al. National prescription patterns of antidepressants in the treatment of adults with major depression in the US between 1996 and 2015: a population representative survey based analysis. Front Psychiatry. 2020;11:35.
   PubMed Web of Science ®Google Scholar
• Sansone RA, Sansone LA. SSRI-induced indifference. Psychiatry (Edgmont). 2010;7(10):14–18.
   Google Scholar
• Rosenblat JD, Simon GE, Sachs GS, et al. Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. J Affect Disord. 2019;243:116–120.
   PubMed Web of Science ®Google Scholar
• Ma H, Cai M, Wang H. Emotional blunting in patients with major depressive disorder: a brief non-systematic review of current research. Front Psychiatry. 2021;12:792960.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Rosenblat JD, Nemeroff CB, et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation. Am J Psychiatry. 2021;178(5):385–399.
   Web of Science ®Google Scholar
• Iosifescu DV, Jones A, O’Gorman C, et al. Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI). J Clin Psychiatry. 2022;83(4):21m14345.
   PubMed Web of Science ®Google Scholar
• Kryst J, Kawalec P, Mitoraj AM, et al. Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials. Pharmacol Rep. 2020;72(3):543–562.
   PubMed Web of Science ®Google Scholar
• Ng J, Rosenblat JD, Lui LMW, et al. Efficacy of ketamine and esketamine on functional outcomes in treatment-resistant depression: a systematic review. J Affect Disord. 2021;293:285–294.
   PubMed Web of Science ®Google Scholar
• Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med. 2007;167(2):188–194.
   PubMedGoogle Scholar
• Kang S, Han M, Park CI, et al. Use of serotonin reuptake inhibitors and risk of subsequent bone loss in a nationwide population-based cohort study. Sci Rep. 2021;11(1):13461.
   PubMed Web of Science ®Google Scholar
• Faquih AE, Memon RI, Hafeez H, et al. A review of novel antidepressants: a guide for clinicians. Cureus. 2019;11(3):e4185.
   PubMed Web of Science ®Google Scholar
• De Bodinat C, Guardiola-Lemaitre B, Mocaer E, et al. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov. 2010;9(8):628–642.
   PubMed Web of Science ®Google Scholar
• Rosenbaum SB, Gupta V, Patel P, et al. Ketamine. Updated 2022 Nov 24. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470357/
   Google Scholar
• Salahudeen M, Wright CM, Peterson GM. Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review. Ther Adv Drug Saf. 2020;11:1–23.
   Web of Science ®Google Scholar
• Cosci F, Chouinard G. The monoamine hypothesis of depression revisited: could it mechanistically novel antidepressant strategies? In: Quevedo J, Carvalho AF, Zarate CA, eds. Neurobiology of Depression: Road to Novel Therapeutics. London: Academic Press. 2019. 63–73.
   Google Scholar
• Sub Laban T, Saadabadi A. Monoamine oxidase inhibitors (MAOI). Treasure Island (FL): StatPearls Publishing; 2022.
   Google Scholar
• Suchting R, Tirumalajaru V, Gareeb R, et al. Revisiting monoamine oxidase inhibitors for the treatment of depressive disorders: a systematic review and network meta-analysis. J Affect Disord. 2021;282:1153–1160.
   PubMed Web of Science ®Google Scholar
• Bodkin JA, Dunlop BW. Moving on with monoamine oxidase inhibitors. Focus (Am Psychiatr Publ). 2021;19(1):50–52.
   PubMedGoogle Scholar
• Grady MM, Stahl SM. Practical guide for prescribing MAOIs: debunking myths and removing barriers. CNS Spectr. 2012;17(1):2–10.
   PubMed Web of Science ®Google Scholar
• Chu A, Wadhwa R. Selective serotonin reuptake inhibitors. Treasure Island (FL): StatPearls Publishing; 2022.
   Google Scholar
• Carvalho AF, Sharma MS, Brunoni AR, et al. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. Psychother Psychosom. 2016;85(5):270–288.
   PubMed Web of Science ®Google Scholar
• Warden SJ, Fuchs RK. Do selective serotonin reuptake inhibitors (SSRIs) cause fractures? Curr Osteoporos Rep. 2016;14(5):211–218.
   PubMed Web of Science ®Google Scholar
• FDA. In: FDA Drug Safety Communication: revised recommendations for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses [Internet]. updated 2012 Mar 28. Silver Spring (MD): Food and Drug Administration. Available fromhttps://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-revised-recommendations-celexa-citalopram-hydrobromide-related
   Google Scholar
• Yuet WC, Derasari D, Sivoravong J, et al. Selective serotonin reuptake inhibitor use and risk of gastrointestinal and intracranial bleeding. J Am Osteopath Assoc. 2019;119(2):102–111.
   PubMed Web of Science ®Google Scholar
• Sansone RA, Sansone LA. Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci. 2014;11(3–4):37–42.
   PubMedGoogle Scholar
• Perahia DG, Pritchett YL, Kajdasz DK, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. J Psychiatr Res. 2008;42(1):22–34.
   PubMed Web of Science ®Google Scholar
• Fava GA, Benasi G, Lucente M, et al. Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review. Psychother Psychosom. 2018;87(4):195–203.
   PubMed Web of Science ®Google Scholar
• Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom. 2020;89(5):283–306.
   PubMed Web of Science ®Google Scholar
• Thase ME, Nierenberg AA, Vrijland P, et al. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. Int Clin Psychopharmacol. 2010;25(4):189–198.
   PubMed Web of Science ®Google Scholar
• Jilani TN, Gibbons JR, Faizy RM, et al. Mirtazapine. Treasure Island (FL): StatPearls Publishing; 2022.
   Google Scholar
• Croom KF, Perry CM, Plosker GL. Mirtazapine: a review of its use in major depression and other psychiatric disorders. CNS Drugs. 2009;23(5):427–452.
   PubMed Web of Science ®Google Scholar
• Shin JJ, Saadabadi A. Trazodone. Treasure Island (FL): StatPearls Publishing; 2022.
   Google Scholar
• Jaffer KY, Chang T, Vanle B, et al. Trazodone for insomnia: a systematic review. Innov Clin Neurosci. 2017;14(7–8):24–34.
   PubMedGoogle Scholar
• Goracci A, Forgione RN, De Giorgi R, et al. Practical guidance for prescribing trazodone extended-release in major depression. Expert Opin Pharmacother. 2016;17(3):433–441.
   PubMed Web of Science ®Google Scholar
• Staiger B. What is agomelatine and why isn’t it available in the United States? [Internet]. Updated 2019 Oct 28. Available from. https://walrus.com/articles/what-is-agomelatine-and-why-isn-t-it-available-in-the-united-states
   Google Scholar
• Kennedy SH, Lam RW, McIntyre RS, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 3. Pharmacological treatments. Can J Psychiatry. 2016;61(9):540–560.
   PubMed Web of Science ®Google Scholar
• Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: pharmacokinetic and formulation considerations. Clin Ther. 2005;27(11):1685–1695.
   PubMed Web of Science ®Google Scholar
• Patel K, Allen S, Haque MN, et al. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol. 2016;6(2):99–144.
   PubMed Web of Science ®Google Scholar
• Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. Pharmacol Ther. 2015;145:43–57.
   PubMed Web of Science ®Google Scholar
• Citrome L. Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out. Int J Clin Pract. 2015;69(2):151–155.
   PubMed Web of Science ®Google Scholar
• Wang SM, Han C, Lee SJ, et al. Vilazodone for the treatment of depression: an update. Chonnam Med J. 2016;52(2):91–100.
   PubMedGoogle Scholar
• Trintellix [package insert]. Deerfield. IL: Takeda Pharmaceuticals America, Inc; 2021.
   Google Scholar
• Montano CB, Jackson WC, Vanacore D, et al. Practical advice for primary care clinicians on the safe and effective use of vortioxetine for patients with major depressive disorder (MDD). Neuropsychiatr Dis Treat. 2022;18:867–879.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Dextromethorphan/bupropion: a novel oral NMDA (N-methyl-d-aspartate) receptor antagonist with multimodal activity. CNS Spectr. 2019;24(5):461–466.
   PubMed Web of Science ®Google Scholar
• Messer MM, Haller IV. Minn Med.2018;November/December:36–40.
   Google Scholar
• Sanacora G, Frye MA, McDonald W, et al. A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry. 2017;74(4):399–405.
   PubMed Web of Science ®Google Scholar
• Auvelity [package insert]. New York NY: Axsome Therapeutics, Inc; 2022.
   Google Scholar
• Khabir Y, Hashmi MR, Ali Asghar A. Rapid-acting oral drug (Auvelity) for major depressive disorder. Ann Med Surg (Lond). 2022;82:104629.
   PubMed Web of Science ®Google Scholar
• Ng CW, How CH, Ng YP. Depression in primary care: assessing suicide risk. Singapore Med J. 2017;58(2):72–77.
   PubMed Web of Science ®Google Scholar
• Seok Seo J, Rim Song H, Bin Lee H, et al. The Korean medication algorithm for depressive disorder: second revision. J Affect Disord. 2014;167:312–321.
   PubMed Web of Science ®Google Scholar
• Bond DJ, Hadjipavlou G, Lam RW, et al. The Canadian network for mood and anxiety treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry. 2012;24(1):23–37.
   PubMed Web of Science ®Google Scholar
• Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–1366.
   PubMed Web of Science ®Google Scholar
• Del Casale A, Pomes LM, Bonanni L, et al. Pharmacogenomics-guided pharmacotherapy in patients with major depressive disorder or bipolar disorder affected by treatment-resistant depressive episodes: a long-term follow-up study. J Pers Med. 2022;12(2):316.
   PubMed Web of Science ®Google Scholar
• Li Z, Ruan M, Chen J, et al. Major depressive disorder: advances in neuroscience research and translational applications. Neurosci Bull. 2021;37(6):863–880.
   PubMed Web of Science ®Google Scholar
• Carvajal C. Poor response to treatment: beyond medication. Dialogues Clin Neurosci. 2004;6(1):93–103.
   PubMedGoogle Scholar
• Cartwright C, Gibson K, Read J, et al. Long-term antidepressant use: patient perspectives of benefits and adverse effects. Patient Prefer Adherence. 2016;10:1401–1407.
   PubMed Web of Science ®Google Scholar
• McIntyre RS. Using measurement strategies to identify and monitor residual symptoms. J Clin Psychiatry. 2013;74(Suppl 2):14–18.
   PubMedGoogle Scholar
• McIntyre RS, Patel MD, Masand PS, et al. The Rapid Mood Screener (RMS): a novel and pragmatic screener for bipolar I disorder. Curr Med Res Opin. 2021;37(1):135–144.
   PubMed Web of Science ®Google Scholar
• Ratheesh A, Davey C, Hetrick S, et al. A systematic review and meta-analysis of prospective transition from major depression to bipolar disorder. Acta Psychiatr Scand. 2017;135(4):273–284.
   PubMed Web of Science ®Google Scholar
• Gitlin MJ. Antidepressants in bipolar depression: an enduring controversy. Int J Bipolar Disord. 2018;6(1):25.
   PubMedGoogle Scholar
• McElroy SL, Kotwal R, Kaneria R, et al. Antidepressants and suicidal behavior in bipolar disorder. Bipolar Disord. 2006;8(5 Pt 2):596–617.
   PubMed Web of Science ®Google Scholar
• Kishi T, Ikuta T, Matsuda Y, et al. Mood stabilizers and/or antipsychotics for bipolar disorder in the maintenance phase: a systematic review and network meta-analysis of randomized controlled trials. Mol Psychiatry. 2021;26(8):4146–4157.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Talbot PS, Anderson IM, et al. Managing inadequate antidepressant response in depressive illness. Br Med Bull. 2015;115(1):183–201.
   PubMed Web of Science ®Google Scholar
• Chan HN, Mitchell PB, Loo CK, et al. Pharmacological treatment approaches to difficult-to-treat depression. Med J Aust. 2013;199(Suppl 6):S44–S47.
   PubMed Web of Science ®Google Scholar
• McIntosh D, Kutcher S, Binder C, et al. Adult ADHD and comorbid depression: a consensus-derived diagnostic algorithm for ADHD. Neuropsychiatr Dis Treat. 2009;5:137–150.
   PubMed Web of Science ®Google Scholar
• Sternat T, Katzman MA. Neurobiology of hedonic tone: the relationship between treatment-resistant depression, attention-deficit hyperactivity disorder, and substance abuse. Neuropsychiatr Dis Treat. 2016;12:2149–2164.
   PubMed Web of Science ®Google Scholar
• Canadian ADHD Resource Alliance (CADDRA). Canadian ADHD practice guidelines. 4th ed. Toronto (ON): CADDRA; 2018.
   Google Scholar
• Verbeeck W, Bekkering GE, Van den Noortgate W, et al. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2017;10(10):CD009504.
   PubMedGoogle Scholar
• Yu C, Garcia-Olivares J, Candler S, et al. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285–300.
   PubMedGoogle Scholar
• Qelbree [package insert]. Rockville. MD: Supernus Pharmaceuticals Inc; 2022.
   Google Scholar
• Kinrys G, Gold AK, Pisano VD, et al. Tachyphylaxis in major depressive disorder: a review of the current state of research. J Affect Disord. 2019;245:488–497.
   PubMed Web of Science ®Google Scholar
• MacQueen G, Santaguida P, Keshavarz H, et al. Systematic review of clinical practice guidelines for failed antidepressant treatment response in major depressive disorder, dysthymia, and subthreshold depression in adults. Can J Psychiatry. 2017;62(1):11–23.
   PubMed Web of Science ®Google Scholar
• Durgam S, Earley W, Guo H, et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder. J Clin Psychiatry. 2016;77(3):371–378.
   PubMed Web of Science ®Google Scholar
• Lam RW, Parikh SV, Michalak EE, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. Ann Clin Psychiatry. 2015;27(2):142–149.
   PubMed Web of Science ®Google Scholar
• Evans VC, Alamian G, McLeod J, et al. The effects of newer antidepressants on occupational impairment in major depressive disorder: a systematic review and meta-analysis of randomized controlled trials. CNS Drugs. 2016;30(5):405–417.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Cha DS, Soczynska JK, et al. Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. Depress Anxiety. 2013;30(6):515–527.
   PubMed Web of Science ®Google Scholar
• Baune BT, Renger L. Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression—a systematic review. Psychiatry Res. 2014;219(1):25–50.
   PubMed Web of Science ®Google Scholar
• Pan Z, Grovu RC, Cha DS, et al. Pharmacological treatment of cognitive symptoms in major depressive disorder. CNS Neurol Disord Drug Targets. 2017;16(8):891–899.
   PubMed Web of Science ®Google Scholar
• Haro JM, Hammer-Helmich L, Saragoussi D, et al. Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study. Neuropsychiatr Dis Treat. 2019;15:2313–2323.
   PubMed Web of Science ®Google Scholar
• Sumiyoshi T, Hoshino T, Mishiro I, et al. Prediction of residual cognitive disturbances by early response of depressive symptoms to antidepressant treatments in patients with major depressive disorder. J Affect Disord. 2022;296:95–102.
   PubMed Web of Science ®Google Scholar
• Mattingly GW, Ren H, Christensen MC, et al. Effectiveness of vortioxetine in patients with major depressive disorder in real-world clinical practice: results of the RELIEVE study. Front Psychiatry. 2022;13:824831.
   PubMedGoogle Scholar
• Fang H, Tu S, Sheng J, et al. Depression in sleep disturbance: a review on a bidirectional relationship, mechanisms and treatment. J Cell Mol Med. 2019;23(4):2324–2332.
   PubMed Web of Science ®Google Scholar
• Wang YQ, Li R, Zhang MQ, et al. The neurobiological mechanisms and treatments of REM sleep disturbances in depression. Curr Neuropharmacol. 2015;13(4):543–553.
   PubMed Web of Science ®Google Scholar
• Alberti S, Chiesa A, Andrisano C, et al. Insomnia and somnolence associated with second-generation antidepressants during the treatment of major depression: a meta-analysis. J Clin Psychopharmacol. 2015;35(3):296–303.
   PubMed Web of Science ®Google Scholar
• Goodwin GM, Price J, De Bodinat C, et al. Emotional blunting with antidepressant treatments: a survey among depressed patients. J Affect Disord. 2017;221:31–35.
   PubMed Web of Science ®Google Scholar
• Read J, Cartwright C, Gibson K. Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants. Psychiatry Res. 2014;216(1):67–73.
   PubMed Web of Science ®Google Scholar
• Wongpakaran N, van Reekum R, Wongpakaran T, et al. Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: a case-control study. Ann Gen Psychiatry. 2007;6:7.
   PubMedGoogle Scholar
• Christensen MC, Fagiolini A, Florea I, et al. Validation of the Oxford Depression Questionnaire: sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting. J Affect Disord. 2021;294:924–931.
   PubMed Web of Science ®Google Scholar
• Corruble E, de Bodinat C, Belaidi C, et al. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. Int J Neuropsychopharmacol. 2013;16(10):2219–2234.
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Florea I, Loft H, et al. Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment. J Affect Disord. 2021;283:472–479.
   PubMed Web of Science ®Google Scholar
• Goodwin GM. Revisiting treatment options for depressed patients with generalised anxiety disorder. Adv Ther. 2021;38(Suppl 2):61–68.
   PubMed Web of Science ®Google Scholar
• Zareifopoulos N, Dylja I. Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: a meta-analysis. Asian J Psychiatr. 2017;26:115–122.
   PubMed Web of Science ®Google Scholar
• Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019;393(10173):768–777.
   PubMed Web of Science ®Google Scholar
• Christensen MC, Schmidt S, Grande I. Effectiveness of vortioxetine in patients with major depressive disorder comorbid with generalized anxiety disorder: results of the RECONNECT study. J Psychopharmacol. 2022;36(5):566–577.
   PubMed Web of Science ®Google Scholar